Spinning molecular immunology into successful immunotherapy

Nature Reviews Immunology

Volumn 2, Issue 4, 2002, Pages 227-238

  Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPITOPE; IMMUNOGLOBULIN IDIOTYPE; IMMUNOLOGICAL ADJUVANT; PEPTIDE; PROTEIN; TRANSCRIPTOME; TUMOR ANTIGEN; VACCINE; VIRUS VECTOR; CANCER VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BACTERIUM; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL ORGANELLE; CROSS PRESENTATION; CYTOLOGY; DENDRITIC CELL; EXPRESSION VECTOR; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR BIOLOGY; MOLECULAR IMMUNOLOGY; NONHUMAN; PRIME BOOST; PRIORITY JOURNAL; RECOMBINANT BACTERIUM; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS RECOMBINANT; ANIMAL; GENE VECTOR; GENETICS; HUMAN; NEOPLASM; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036548986     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri774     Document Type: Review

References (139)

1. Haywood, G. R. & McKhann, C. F. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J. Exp. Med. 133, 1171-1187 (1971).
2. Hui, K., Grosveld, F. & Festenstein, H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750-752 (1984).
3. Travers, P. J., Arklie, J. L., Trowsdale, J., Patillo, R. A. & Bodmer, W. F. Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines. Natl Cancer Inst. Monogr. 60, 175-180 (1982).
4. Kaklamanis, L. et al. Loss of HLA class-I alleles, heavy chains and β2-microglobulin in colorectal cancer. Int. J. Cancer 51, 379-385 (1992).
5. Restifo, N. P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272 (1993).
6. Torre, A. G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486-1490 (1990).
7. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671-2679 (1996).
8. Speiser, D. E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645-653 (1997).
9. Staveley-O'Carroll, K. et al. Induction of antigen-specific T-cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178-1183 (1998).
10. Wick, M. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T-cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238 (1997).
11. + T cells in the anti-tumor immune response. J. Exp. Med. 188, 2357-2368 (1998).
12. Qin, Z. et al. B cells inhibit induction of T-cell-dependent tumor immunity. Nature Med. 4, 627-630 (1998).
13. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
14. Munger, K. et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099-4105 (1989).
15. Galloway, D. A. & Jenison, S. A. Characterization of the humoral immune response to genital papillomaviruses. Mol. Biol. Med. 7, 59-72 (1990).
16. Howley, P. M. in Fundamental Virology (eds Fields, B. N. & Knipe, D. M.) 743-763 (Raven, New York, 1991).
17. Beasley, R. P., Hwang, L. Y., Lin, C. C. & Chien, C. S. Hepatocellular carcinoma and hepatitis B virus A prospective study of 22 707 men in Taiwan. Lancet 2, 1129-1133 (1981).
18. Brechot, C. What is the role of hepatitis B virus in the appearance of hepatocellular carcinomas in patients with alcoholic cirrhosis? Gastroenterol. Clin. Biol. 6, 727-730 (1982).
19. Szmuness, W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a casual association. Prog. Med. Virol. 24, 40-46 (1987).
20. Shafritz, D. A., Shouval, D., Sherman, H. I., Hadziyannis, S. J. & Kew, M. C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med. 305, 1967-1973 (1981).
21. zur Hausen, H., Schulte-Holthausen, H. & Klein, G. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1059 (1970).
22. Weiss, L. M., Movahed, L. A., Warnke, R. A. & Sklar, J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320, 502-506 (1989).
23. Wu, T. C. et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int. J. Cancer 46, 801-804 (1990).
24. Steinman, R. M. The dendritic-cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
25. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
26. Inaba, K. et al. Identification of proliferating dendritic-cell precursors in mouse blood. J. Exp. Med. 175, 1157-1167 (1992).
27. Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261 (1992).
28. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukocyte Biol. 59, 208-218 (1996).
29. Romani, N. R. D. et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151 (1996).
30. Maraskovsky, E, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3-ligand-treated mice: multiple dendritic-cell subpopulations identified. J. Exp. Med. 184, 1953-1962 (1996).
31. Akira, S. T. K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2, 675-680 (2001).
32. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118 (1994).
33. Caux, C. et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263-1272 (1994).
34. Cella, M. et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752 (1996).
35. Cella, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-787 (1997).
36. Pierre, P. et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787-792 (1997).
37. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993). Comprehensive comparison of the relative efficacies of whole-cell tumour vaccines engineered to secrete a panel of different cytokines. This study identified GM-CSF-transduced tumour vaccines as uniquely generating potent systemic antitumour immunity and provided an in vivo correlate to the studies that showed the role of GM-CSF in the induction of DC differentiation.
38. Pardoll, D. M. & Jaffee, E. M. in Principles and Practice of Biologic Therapy of Cancer (Silverchair, Charlottesville, 1999).
39. Chiodoni, C. et al. Dendritic cells infiltrating tumors cotransduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T-lymphocyte response. J. Exp. Med. 190, 125-133 (1999). Demonstration of the enhanced effectiveness of engineered tumour-cell vaccines that secrete a combination of DC mitogen (GM-CSF) and activation (CD40L) factors in locally activating DCs and producing systemic antitumour immunity.
40. Tao, M. H. & Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758 (1993).
41. Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903 (2000).
42. Tendler, D. S. et al. Intersection of interferon and hypoxia signal-transduction pathways in nitric-oxide-induced tumor apoptosis. Cancer Res. 61, 3682-3688 (2001).
43. Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
44. Soiffer, R. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 95, 13141-13146 (1998).
45. Jaffee, E. M. et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156 (2001).
46. Porgador, A. & Gilboa, E. Bone-marrow-generated dendritic cells pulsed with a class-I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182, 255-260 (1995).
47. Mayordomo, J. I. et al. Bone-marrow-derived dendritic cells pulsed with syn thetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
48. Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor-lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
49. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
50. Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322 (1996).
51. Lambert, L. A., Gibson, G. R., Maloney, M. & Barth, R. J. Jr. Equipotent generation of protective antitumor immunity by various methods of dendritic-cell loading with whole cell tumor antigens. J. Immunother. 24, 232-236 (2001).
52. Shimizu, K., Thomas, E. K., Giedlin, M. & Mule, J. J. Enhancement of tumor lysate- and peptide-pulsed dendritic-cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61, 2618-2624 (2001).
53. Song, W. et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256 (1997).
54. Specht, J. M. et al. Dendritic cells retrovirally transduced with a model tumor antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213-1221 (1997).
55. Dyall, J., Latouche, J. B., Schnell, S. & Sadelain, M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97, 114-121 (2001).
56. Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
57. Reddy, A., Sapp, M., Feldman, M., Subklewe, M. & Bhardwai, N. A monocyte-conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendntic cells. Blood 90, 3640-3646 (1997).
58. Bender, A. S. M., Schuler, G., Steinman, R. M. & Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196, 121-135 (1996).
59. Klein, C., Bueler, H. & Mulligan, R. C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191, 1699-1708 (2000).
60. Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558-561 (1997).
61. Boyle, J. S., Brady, J. L. & Lew, A. M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392, 408-411 (1998).
62. You, Z., Huang, X., Hester, J., Toh, H. C. & Chen, S. Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61, 3704-3711 (2001).
63. Mahnke, K. et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151, 673-684 (2000).
64. Srivastava, P. K. Roles of heat-shock proteins in innate and adaptive immunity. Nature Rev. Immunol. 2, 185-194 (2002).
65. Tamura, Y., Peng, P., Liu, K., Daou, M. & Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat-shock protein preparations. Science 278, 117-120 (1997).
66. Udono, H. & Srivastava, P. K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90 and hsp70. J. Immunol. 152, 5398-5403 (1994).
67. Arnold, D., Faath, S., Rammensee, H. & Schild, H. Cross-priming of minor histocompatibity antigen-specific cytotoxic T cells upon immunization with the heat-shock protein gp96. J. Exp. Med. 182, 885-889 (1995).
68. Wang, X. Y., Kazim, L., Repasky, E. A. & Subjeck, J. R. Charactenzation of heat-shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166, 490-497 (2001).
69. Suzue, K., Zhou, X., Eisen, H. N. & Young, R. A. Heat-shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl Acad. Sci. USA 94, 13146-13151 (1997).
70. Castellino, F. et al. Receptor-mediated uptake of antigen/heat-shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 191, 1957-1964 (2000).
71. Chen, C. H. et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60, 1035-1042 (2000). References 65-71 indicate the different ways that various heat-shock proteins have been used to enhance tumour vaccine potency.
72. Suto, R. & Srivastava, P. K. A mechanism for the specific immunogenicity of heat-shock-protein-chaperoned peptides. Science 269, 1585-1588 (1995).
73. Basu, S., Binder, R. J., Ramalingam, T. & Srivastava, P. K. CD91 is a common receptor for heat-shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity 14, 303-313 (2001).
74. Asea, A. et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nature Med. 6, 435-442 (2000). Shows the ability of heat-shock proteins to act as activation signals for antigen-presenting cells.
75. Kuppner, M. C. et al. The role of heat-shock protein (hsp70) in dendritic-cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur. J. Immunol. 31, 1602-1609 (2001).
76. Boniface, J. J. & Davis, M. M. T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Ann. NY Acad. Sci. 766, 62-69 (1995).
77. Boon, T. O. L. Cancer tumor antigens. Curr. Opin. Immunol. 9, 681-683 (1997).
78. Robbins, P. F. & Kawakami, Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8, 628-636 (1996).
79. Parkhurst, M. R. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157, 2539-2548 (1996).
80. Dyall, R. et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553-1561 (1998). References 79 and 80 show that modification of MHC anchor residues in a tumour peptide antigen can significantly enhance MHC binding without disrupting recognition by T cells specific for the wild-type peptide. Anchor modification is now commonly used to enhance the efficacy of peptide vaccines.
81. Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529-538 (2000). Shows that modification of residues in an antigenic peptide that increase TCR affinity can increase the stimulation of significant repertoires of T cells specific for the wild-type peptide.
82. Wu, T. C. et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl Acad. Sci. USA 92, 11671-11675 (1995).
83. Lin, K. Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26 (1996).
84. Ji, H. et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10, 2727-2740 (1999).
85. Hung, C. F. et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol. 166, 5733-5740 (2001).
86. Hung, C. F. et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698-3703 (2001).
87. Livingston, B. D. et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19, 4652-4660 (2001).
88. + T cells by B7-transfected melanoma cells. Science 259, 368-370 (1993).
89. Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992).
90. Huang, A. Y., Bruce, A. T., Pardoll, D. M. & Levitsky H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776 (1996).
91. Kim, J. J. et al. Engineering of in vivo immune responseś to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnol. 15, 641-646 (1997).
92. Agadianyan, M. G. et al. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J. Immunol. 162, 3417-3427 (1999).
93. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997).
94. Weinberg, A. D. et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164, 2160-2169 (2000).
95. Bansal-Pakala, P., Jember, A. G. & Croft, M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nature Med. 7, 907-912 (2001).
96. Atkins, M. B. et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
97. Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D. & Reisfeld, R. A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80, 277-292 (1998).
98. Ahlers, J. D., Dunlop, N., Alling, D. W., Nara, P. L. & Berzofsky, J. A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158, 3947-3958 (1997).
99. Smith, G. L., Murphy, B. R. & Moss, B. Construction and charactenzation of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl Acad. Sci. USA 80, 7155-7159 (1983).
100. Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 80, 5364-5368 (1983).
101. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc. Natl Acad. Sci. USA 93, 11341-11348 (1996).
102. Carroll, M. W. et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15, 387-394 (1997).
103. Paoletti, E., Taylor, J., Meignier, B., Meric, C. & Tartaglia, J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 84, 159-163 (1995).
104. Velders, M. P. et al. Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61, 7861-7867 (2001).
105. Elzey, B. D., Siemens, D. R., Ratliff, T. L. & Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849 (2001).
106. Gewurz, B. E., Gaudet, R., Tortorella, D., Wang, E. W. & Ploegh, H. L. Virus subversion of immunity: a structural perspective. Curr. Opin. Immunol. 13, 442-450 (2001).
107. Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime-boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595-1601 (1997).
108. Ramshaw, I. A. & Ramsay, A. J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21, 163-165 (2000).
109. Pan, Z. K., Ikonomidis, G., Lazenby, A., Pardoll, D. M. & Paterson, Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med. 1, 471-477 (1995).
110. Thole, J. E. et al. Live bacterial delivery systems for development of mucosal vaccines. Curr. Opin. Mol. Ther. 2, 94-99 (2000).
111. Killeen, K., Spriggs, D. & Mekalanos, J. Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. Curr. Top. Microbiol. Immunol. 236, 237-254 (1999).
112. Ohara, N. & Yamada, T. Recombinant BCG vaccines. Vaccine 19, 4089-4098 (2001).
113. Shata, M. T., Stevceva, L., Agwale, S., Lewis, G. K. & Hone, D. M. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 6, 66-71 (2000).
114. Sizemore, D. R., Branstrom, A. A. & Sadoff, J. C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299-302 (1995).
115. Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775 (1997).
116. Chambers, C. A., Kuhns, M. S. Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
117. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
118. Hurwitz, A. A., Yu, T. F., Leach, D. R. & Allison, J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95, 10067-10071 (1998).
119. Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444-2448 (2000).
120. Dong, H., Zhu, G., Tamada, K. & Chen, L. BT-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365-1369 (1999).
121. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
122. Tseng, S.-Y. et al. B7-DC, a new dendritic-cell molecule with unique costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
123. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibitst-cell activation. Nature Immunol. 2, 261-268 (2001).
124. Ibarra-Sanchez, M. J. et al. The T-cell protein tyrosine phosphatase. Semin. Immunol. 12, 379-386 (2000).
125. Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349-354 (2001).
126. Greenhalgh, C. J. & Hilton, D. J. Negative regulation of cytokine signaling. J. Leukocyte Biol. 70, 348-356 (2001).
127. Vang, T. et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP dependent protein kinase inhibits signaling through the T-cell receptor. J. Exp. Med. 193, 497-507 (2001).
128. Chiang, Y. J. et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216-220 (2000).
129. Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl.b. Nature 403, 211-216 (2000).
130. Sun, L. et al. Cabin 1, a negative regulator for calcineudn signaling in T lymphocytes. Immunity 8, 703-711 (1998).
131. Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810-11813 (1995).
132. Gure, A. O. et al. SSX: a multigene family with several members transcribed in normal testis and human cancer Int. J. Cancer 72, 965-971 (1997).
133. Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995). A combination of a GM-CSF-transduced melanoma cell vaccine and anti-CTLA4 antibodies are used to show that in vivo CTLA4 blockade can amplify vaccine potency significantly. As in reference 27, anti-melanoma activity correlated with induction of vitiligo.
134. Fossum, B. et al. A K-ras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int. J. Cancer 58, 506-511 (1994). Clinical survey of melanoma patients treated with different immunotherapies, showing that virtually all patients who develop therapy-related vitiligo have partial or complete tumour regression.
135. + T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int. J. Cancer 56, 40-45 (1994). First application of expression cloning to identify a human tumour antigen. The MAGE family is an important set of shared tumour antigens selectively expressed in tumours and testes but not in other normal adult tissues.
136. Kwak, L. W., Young, H. A., Pennington, R. W. & Weeks, S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93, 10972-10977 (1996).
137. + T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982-2987 (1999).
138. Rosenberg, S. A. & White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Tumor Immunol. 19, 81-84 (1996).
139. Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).